San Diego-based clinical and life science detection tools developer Genalyte Inc. has announced it is collaborating with the Barbara Davis Center for Childhood Diabetes at the University of Colorado School of Medicine to further develop and test multiplexed antigen panels for the early detection of Type 1 diabetes.
In conjunction with the announcement, the company also reported the launch of its Type 1 diabetes antigen panel running on its Maverick detection system. The Genalyte T1D antigen panel is the first multiplexed assay that measures seven autoantibodies associated with the destruction of pancreatic islet cells seen in type 1 diabetes, a Genalyte release said.
The launched antigen panel was developed as part of the first phase of a $500,000 Small Business Innovation Research grant awarded to Genalyte from the National Institute of Diabetes and Digestive and Kidney Diseases. The grant also is also providing support for expansion of the approach to allow autoantibody response profiling by multiple criteria, which Genalyte said is expected to enhance the ability of researchers and clinicians to detect and monitor the development of the disease.
Martin Gleeson, chief scientific officer of Genalyte, said the work of Dr. George Eisenbarth and Dr. Liping Yu at the Barbara Davis Center for Childhood Diabetes is responsible for establishing assays for the measurement of islet autoantibodies, rogue elements of the immune system that eventually destroy the pancreatic islet cells that produce insulin.
"The unique capabilities of our Maverick detection platform have the potential to provide researchers and clinicians with tools to detect and track this process from an early stage, when interventions to interrupt the disease process may be feasible," Gleeson said.